Minaris Advanced Therapies vs WuXi Biologics: CDMO Comparison
How does Minaris Advanced Therapies compare to WuXi Biologics?
As of Aug 2026, Minaris Advanced Therapies: 3 FDA inspections (including 2 NAI, 1 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 83.1. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Minaris Advanced Therapies and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- WuXi Biologics maintains 1 MHRA / UK GMP certificate; Minaris Advanced Therapies does not.
Across the cross-modality scorecard, Minaris Advanced Therapies carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Minaris Advanced Therapies vs WuXi Biologics
How does Minaris Advanced Therapies compare to WuXi Biologics?
On CDMO Signal's composite Signal Score, Minaris Advanced Therapies is 83/100 and WuXi Biologics is 83/100; Minaris Advanced Therapies has 3 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 2 active EMA+MHRA certificates for Minaris Advanced Therapies vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Minaris Advanced Therapies or WuXi Biologics?
Both Minaris Advanced Therapies and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Minaris Advanced Therapies has 3 FDA inspections on record; WuXi Biologics has 1.
How do Minaris Advanced Therapies and WuXi Biologics compare on European GMP coverage?
Minaris Advanced Therapies holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Minaris Advanced Therapies carries a Signal Score of 83/100 and WuXi Biologics carries 83/100 — essentially tied for Minaris Advanced Therapies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →